

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 31/135, 9/70, 47/48		A1	(11) International Publication Number: WO 93/19746
			(43) International Publication Date: 14 October 1993 (14.10.93)
(21) International Application Number: PCT/FI93/00119		(81) Designated States: AT, AU, CA, CH, DE, DK, ES, FI, GB, HU, JP, LU, NL, NO, NZ, PT, RU, SE, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 25 March 1993 (25.03.93)			
(30) Priority data: 9207437.6 3 April 1992 (03.04.92) GB		Published With international search report.	
(71) Applicant (for all designated States except US): ORION-YH-TYMÄ OY [FI/FI]; Orionintie 1, SF-02200 Espoo (FI).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): DEGREGORIO, Michael, William [US/US]; 15655 Robin Ridge Road, San Antonio, TX (US). KURKELA, Kauko, Oiva, Antero [FI/FI]; Pampinkuja 1 C, SF-20900 Turku (FI).			
(74) Agent: ORION CORPORATION; Orion-Farmos Pharmaceuticals, Patent Department, P.O. Box 65, SF-02101 Espoo (FI).			
(54) Title: TOPICAL ADMINISTRATION OF TOREMIFENE AND ITS METABOLITES			
(57) Abstract			
<p>Topical preparations containing as active ingredient toremifene or one of its metabolites N-demethyltoremifene or 4-hydroxy-toremifene or their pharmaceutically acceptable non-toxic salts are useful for the treatment of cancers localized in the skin or on a short distance from the skin such as metastatic lesions of breast cancer. They may also be used in adjuvant therapy of breast cancer and in the reversal of multidrug resistance of cancer cells to cytotoxic drugs. Such topical preparations are of particular interest in the treatment of melanoma, lymphoma, Kaposi's sarcoma and fungoides mycosis.</p>			
BEST AVAILABLE COPY			

ATTORNEY DOCKET NUMBER: 10177-216-999
SERIAL NUMBER: 09/590,002
REFERENCE: B99

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

Topical administration of toremifene and its metabolites

This invention relates to topical preparations containing as active ingredient toremifene or one of its metabolites N-demethyltoremifene (4-chloro-1,2-diphenyl-[4-[2-(N-methylamino)ethoxy]phenyl]-1-butene) or 4-hydroxytoremifene (4-chloro-1-(4-hydroxyphenyl)-2-phenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene) or their pharmaceutically acceptable non-toxic salts. The use of such topical preparations e.g. for the treatment of cancers localized in the skin or on a short distance from the skin such as metastatic lesions of breast cancer is also within the scope of the invention. Moreover, the use of these topical preparations for the adjuvant therapy of breast cancer as well as their use for the reversal of multidrug resistance of cancer cells to cytotoxic drugs are also within the scope of the invention. Topical administration of toremifene or its metabolites are of particular interest in the treatment of melanoma, lymphoma, Kaposi's sarcoma and fungoides mycosis.

Tamoxifen and toremifene are triphenylethylene antiestrogens used in the treatment of estrogen receptor positive breast cancer. These drugs are the most frequently prescribed as endocrine agent for the treatment of breast cancer. Tamoxifen and toremifene inhibit estrogen-induced growth by competitive antagonism of tumor estrogen receptors (ER's). Antiestrogen therapy is effective in prolonging a disease-free state and overall survival of women following primary surgery. Antiestrogen therapy delays recurrence and prolongs survival in patients with primary breast cancer undergoing adjuvant therapy after mastectomy. About two-thirds of patients with estrogen receptor (ER) positive metastatic breast cancer will have a temporary remission on tamoxifen. Although tamoxifen is considered a relatively benign drug, recent evidence suggests that women receiving tamoxifen as adjuvant therapy may have increased risk of developing endometrial neoplasms (Fornander T et al, Lancet 1989, 21:117-120). Histopathology identifies these tumors as infiltrating endometrial tumors unrelated to breast tumor metastasis. The factors contributing to this increased risk are not well

understood. However, a variety of studies have linked endometrial cancer to agents with estrogen activity (Smith Dc et al, N England J Med 1975; 293: 1164-67).

The development of multidrug resistance (MDR) is one of the major mechanisms by which cancer becomes refractory to chemotherapeutic agents, especially anthracyclines and the vinca alkaloids. Classical MDR is associated with the overexpression of a *mdr-1* gene that codes for a plasma membrane P-glycoprotein (p170). The expression of the MDR-1 gene is believed to be associated with a decreased cellular accumulation of drug due to an active dependent efflux mechanism.

Although many agents including verapamil, the trifluoperizines, and cyclosporins have been shown to reverse multidrug resistance in vitro, most agents do not achieve high enough in vivo concentrations to reverse without substantial toxicity to the patient. This is particularly true for verapamil which is associated with significant cardiotoxicity.

The non-steroidal triphenylethylene antiestrogens have demonstrated in vitro chemosensitizing activity apparently unrelated to their antiestrogenic effects. Toremifene and its metabolites N-demethyltoremifene and 4-hydroxytoremifene are examples of new triphenylethylenes that have chemosensitizing activity in MDR-positive cells at concentrations that are achieved in humans without significant toxicity. Toremifene appears to be unique in that concentrations that reverse resistance in vitro (5 μM) can be achieved in vivo following oral therapy without substantial toxicity (Wiebe VJ et al, Cancer Chemother Pharmacol, 1990, 25: 247-251). Plasma concentrations of toremifene and N-demethyl-toremifene following large oral doses are on the order of 10 μM . However, plasma concentrations may not reflect the effective anti-MDR activity at the tumor level. Although the systemic toxicity of high-dose toremifene (400 mg/day) is generally confined to vertigo, nausea and hot flashes, combination therapy with other cytotoxic agents may alter the systemic toxicity profile.

Therefore, methods of increasing the tumor concentration of toremifene or its metabolites while minimizing systemic exposure may improve the efficacy of anti-MDR therapy with these drugs.

It has now been found that topical administration of toremifene and its metabolites can be used in order to achieve very high local tumor concentrations without the risk of systemic toxicities. Such topical preparations of toremifene and its metabolites are useful in the treatment of cancers localized in the skin or on a short distance from the skin, such as melanoma, lymphoma, Kaposi's sarcoma, fungoides mycosis and localized metastatic lesions of breast cancer. In addition, topical administration may lead to an effective method of preventing the recurrence of breast cancer in high-risk patients while minimizing the risk of endometrial tumors and systemic toxicity.

The transdermal administration of toremifene and its metabolites can be accomplished mainly in two different ways: (i) by mixing the therapeutically active compound or its non-toxic pharmaceutically acceptable salt with suitable pharmaceutical carriers and optionally penetration enhancers to form ointments, emulsions, lotions, solutions, creams, gels or the like, where preferably an amount of said preparation is applied onto a certain area of skin, or (ii) by incorporating the therapeutically active substance into patches or transdermal delivery systems according to known technology.

Examples of suitable excipients include those well known in the art of pharmacy for the preparation of topical formulations such as DMSO, vegetable and animal oils, non-volatile fatty alcohols, acids, esters, e.g. cetostearyl alcohol and cetyl alcohol; volatile alcoholic compounds, e.g. ethanol or isopropanol; glycols and glycol ethers, polyethylene glycol, polypropylene glycol, glycerol and glycerol ethers, cellulose derivatives, e.g. methylcellulose or carboxymethyl cellulose. Emulsifying agents, e.g. sorbitan stearate or polysorbate 60, and preserving agents and penetration enhancers known in the art may also be included.

The dissolution properties into aqueous media of toremifene and

its metabolites can be significantly improved by complexation of the drug substance with cyclodextrins. Cyclodextrins (including alpha, beta and gamma cyclodextrins and their derivatives) are all cyclic oligomers of glucose. The cyclodextrins can form inclusion complexes with drugs in that drug molecule is included in the lipophile-seeking cavities of the cyclodextrin molecule. Therefore the cyclodextrins effectively solubilize lipophilic drugs into aqueous media. The use of cyclodextrins in the pharmaceutical field has been described e.g. in Drug Development and Industrial Pharmacy, 17(11), 1503-1549, 1991.

Dose range of toremifene or its metabolites for prevention/-adjuvant therapy is in the order of 1 - 200 mg/day/person in humans depending on the bioavailability of the drug. The preferred dose would be close to adjuvant oral dose of 60 mg/day, or a single weekly dose of 300-500 mg/patch. For high-dose short course toremifene (or toremifene metabolite) a dose of 400 - 1000 mg/day is suggested; preferably 500 - 600 mg/day.

EXPERIMENTS

Following extensive studies were carried out to substantiate the present invention:

Experiment 1 describes tissue distribution of toremifene and its metabolites following short course high-dose topical vs. intraperitoneal (IP) administration in the mouse, as well as tissue distribution of antiestrogenic doses of toremifene and its metabolites following single dose topical vs, IP administration.

Experiment 2 describes efficacy of toremifene and its metabolites following topical administration in preventing breast cancer tumor growth in the mouse.

Experiment 3 describes efficacy of high-dose topically administered toremifene in enhancing doxorubicin cytotoxicity in MDR tumors in the mouse.

Experiment 4 describes efficacy of toremifene and its metabolites

following topical administration in preventing lymphoma growth in the baboon.

Experiment 5 describes tissue distribution of toremifene following topical administration in *Monodelphis domestica* and the cytostatic effect of toremifene in melanoma cell lines.

In the drawings,

Fig 1 shows the results of cloning studies performed on the tumors excised from mice treated with topical and intraperitoneal toremifene,

Fig 2 shows the results of cloning studies performed on tumors excised from mice treated with and without topical toremifene,

Fig 3a shows the response observed in baboon right inguinal lymphoma treated with topical toremifene, and

Fig 3b shows the response observed in the untreated baboon left lymphoma.

Experiment 1.

Methods:

Sixteen female athymic nude mice were injected with a 20-gauge needle subcutaneously with 5×10^6 MDA A-1 cells in the left scapular area. The tumors were allowed to grow for three weeks prior to treatment.

For IP administration toremifene citrate was suspended in peanut oil. Each of the three mice were injected IP using an 18 gauge needle with 50 μ l, delivering 1 mg/day for five days. Topical toremifene was administered in a mixture of DMSO/ETOH/methylcellulose/water (10:25:7:58) at a dose of 2.5 mg/animal/day for 5 days. Toremifene citrate was first dissolved in DMSO and then diluted in the mixture of ETOH, methylcellulose and water. All mice were sacrificed on the fifth day of treatment two hours

after the final dose. Blood specimens were collected by capillary pipette after disruption of axillary vessels and placed into heparinized centrifuge tubes. The brains, livers, and uterus were removed surgically and placed in separate tubes.

Single dose toremifene was administered by IP as described above, or topically with DMSO/ETOH/methylcellulose/water as the diluents. The dose of IP or topical toremifene was 500 µg. Tissue samples were collected as above.

All blood samples were centrifuged at 1,000 g. The plasma was collected, measured for volume, and placed in clean extraction tubes. All remaining tissue samples were weighed, placed in extraction tubes, and spiked with an internal standard, nafoxidine. The tissues were thoroughly homogenized before the addition of 6 ml extraction fluid. Samples were collected and dried as described below. Before injection onto the HPLC column, each sample was reconstituted with 200 µl methanol. All samples were placed in a quartz cuvette for UV activation. The brain samples required filtration with disposable syringe filters. Concentrations of toremifene was calculated for all samples based on the standard curve.

Toremifene and its metabolites were quantified by high performance liquid chromatography (HPLC).

Results

Table 1 shows that topically treated tumors had 150 times greater concentrations of toremifene while having a lower serum concentration at 2.5 times the dose of intraperitoneal administration. This indicated a clear pharmacologic advantage. Interestingly, the mice receiving topical toremifene had one-tenth the concentrations in the uterus compared to those receiving IP toremifene. In the liver, the topically treated mice also showed lower toremifene concentrations suggesting less systemic distribution. The toremifene concentrations in the brain tissue were equivalent.

Table 2 shows that the topically treated tumors had a greater concentration of N-demethyltoremifene while having a lower serum concentration. This indicates that MDA A-1 tumor cells may metabolize toremifene. There was essentially no difference in concentration in the liver between the intraperitoneal and topically treated tumors. The brains and uteri of the topically treated mice also showed less N-demethyltoremifene concentration than the IP treated group.

Table 3 shows that the topically treated tumors had greater concentrations of trans 4-hydroxytoremifene than those treated IP. This metabolite is the most potent antiestrogenic metabolite. Serum levels in the topically treated tumors were lower, while in the brain, concentrations were identical.

We also examined the in vitro uptake of toremifene in the MCF-7 ER+ cells at effective antiestrogenic drug doses and compared these studies with the results from the in vivo distribution studies described above. Following 20 hour incubation with 6.6 μM toremifene, cells were washed, counted, weighed and cellular toremifene concentrations were measured by HPLC. The concentration of toremifene ($\mu\text{g}/\text{mg}$) is shown in Table 4.

By comparison to toremifene concentrations achieved in tumors following topical and intraperitoneal routes of administration, the largest concentrations are seen following topical administration of toremifene. Topical administration resulted in greater than 7 times the toremifene concentration found after in vitro exposure and greater than 150 times that found following intraperitoneal injection. These results suggest that the concentrations of toremifene can easily be obtained following topical administration to subcutaneous tumors whereas intraperitoneal administration was 1/20 of the in vitro uptake data, thus suggesting a further kinetic advantage of topical therapy.

Table 5 shows the toremifene concentrations following a single dose of 500 μg IP vs 500 μg administered topically. DMSO and methylcellulose were used as the diluents. Both topically administered methods had similar tumor levels compared to IP but

had much less systemic distribution. This was trend noted in both serum and uterus.

Discussion:

In the experiment, we demonstrate that toremifene readily undergoes transdermal penetration and achieves very high tumor concentrations while limiting systemic exposure. Interestingly, while more toremifene could be delivered topically to the tumors, the serum concentrations were much lower indicating a significant therapeutic advantage for topical delivery of toremifene. In addition, both the active N-demethyl- and 4-hydroxy-metabolites of toremifene were present in greater concentrations in tumor tissue following topical delivery than IP suggesting that metabolism to these active metabolites may also occur at the tissue level rather than exclusively in the liver.

The uterus and liver had much lower toremifene concentrations after topical delivery than IP providing further evidence of reduced systemic exposure with topical therapy. Reduced uterine exposure may be a significant clinical advantage due to the potential risk of secondary tumors to the antiestrogens. Following prolonged adjuvant treatment with tamoxifen, endometrial dysplasia, bleeding, polyp formation and tumors have been reported (Nuovo MA et al Int J Gyn Pathol 1989; 8: 125-131). Tamoxifen metabolites (Bisphenol and metabolite E) following tamoxifen therapy that are present in uterine tissue may potentially be associated with the development of secondary uterine neoplasms (Nuovo MA et al, Int J Gyn Pathol 1989; 21: 117-120). Topical administration of toremifene may circumvent the potential for these side effects.

Experiment 2.

Methods:

In this study 12 mice were transplanted with MCF-7 cells and were allowed to grow until a small tumor was detected in all mice (< 1 mm³). At that time mice were divided into three groups of four

mice each. One group received the diluent alone (DMSO, 20 μ l) topically, the second group received 500 μ g of 4-OH-toremifene by topical administration, and the third received 500 μ g/day of toremifene by topical administration. All mice received the same amount of diluent/day (20 μ l). The study was assessed following 15 days of treatment.

Results:

All four control mice had developed tumors (> 6 x 8 mms). In the other groups only one mouse in the 4-OH-toremifene group developed a small tumor (< 2 x 1 mms). This experiment clearly shows that topical administration of 4-OH-toremifene or toremifene prevented tumor growth.

Discussion:

This experiment clearly demonstrates that adjuvant doses of topically administered toremifene or its metabolites can prevent breast cancer tumor growth in an in vivo mouse model. This result coupled with the kinetic advantage of topical administration (Experiment 1) suggests that topical toremifene can achieve the desired antiestrogenic effects without systemic distribution.

Experiment 3.

Methods:

The topical administration toremifene citrate was dissolved in 1.0 ml of dimethyl sulfoxide (DMSO) resulting in a solution delivering 2.5 mg toremifene/60 μ l. Drug was applied dropwise to the skin surface directly and around the tumor. Each drop was allowed to evaporate completely. This treatment was administered once a day at the same time for a total of five days. All mice were sacrificed on the fifth day of treatment two hours after the final dose. Tumors were collected sterily and processed for clonogenic assay.

Following toremifene administration tumors were excised and a

portion of each tumor was extracted for HPLC analysis. The remaining portion was cloned following a 1 hour exposure to doxorubicin 1 $\mu\text{g/ml}$. The percent inhibition was determined after 14 days, and plotted against the toremifene concentration in each individual tumor.

Results:

Figure 1 shows the results of cloning studies performed on the tumors excised from mice treated with topical and intraperitoneal toremifene. As shown in the graph there was a good correlation between percent inhibition and cellular toremifene concentration at 14 days ($r=0.77$). In addition, all three topically treated tumors achieved $> 30\%$ inhibition, whereas all three intraperitoneal treated tumors had $< 30\%$ inhibition.

Figure 2 shows the results of cloning studies performed on tumors excised from mice treated with and without topical toremifene. The top curve show a tumor resistant to doxorubicin in a mouse not treated with toremifene. The bottom two curves show tumors that were treated with toremifene. Clearly, toremifene appears to sensitize these MDR MDA A-1 tumors to doxorubicin.

Discussion:

These results suggest that the high achievable tumor toremifene concentrations seen with topical toremifene in vivo, the greater the synergistic effects will be at reversing the acquired drug resistance to doxorubicin.

Experiment 4.

Methods

Topical toremifene therapy of a 15-year old female baboon with a spontaneous non-Hodgkin's lymphoma was evaluated. Enlarged lymph nodes with diameters of 1-2 cm were evident in the both groins. Toremifene was dissolved in a mixture of dimethylsulfoxide, ethanol and methylcellulose. Over a period of 8 days, a total of

1.4 g toremifene was applied primarily on the right tumor region. Following 15 days from the start of topical therapy, an oral treatment with 1 g of toremifene on days 15, 17, 19 and 23 was instituted, with a total dose of 4 g. On day 25 following start of treatment, topical therapy of right groin was re-instituted while continuing the oral treatment. During that period, a total of 1.4 g of toremifene was administered transdermally and 11 g orally. The response to therapy was determined by measuring the sizes of the tumors on two perpendicular dimensions.

Results

The response to the therapy is given in Fig 3a and 3b. A clear response was observed in the treated right inguinal lymphoma whereas the untreated left lymphoma increased in size during the topical treatment period. During the oral toremifene therapy the left inguinal lymphoma stabilized, whereas the right inguinal lymphoma began to regrow. Consequently, topical toremifene therapy was reinstituted on this tumor. Similarly to the initial response to topical therapy, the lymphoma regressed from tumor area of 476 mm² to 24 mm².

The treatment of a regional T-cell lymphoma in a female baboon showed that topical toremifene can produce an in vivo antitumor response.

Experiment 5.

Methods

Toremifene in the form of toremifene citrate was first dissolved in DMSO, after which it was added to 3 % methyl cellulose in ethanol to a final concentration of 1 mg/ml.

Six male *Monodelphis domestica* were given toremifene topically for 5 days. The dose was 0.5 mg/d in 3 and 1 mg/d in 3 animals. Toremifene was applied topically to shaved skin on a surface area of 1 cm² of the lower back. At day 5 the animals were sacrificed, and the concentrations of toremifene and its metabolites were

measured in plasma, skin, testicles, liver, eyes, brains and heart.

Three human melanoma cell lines (TD 36, TD 30A and SK-MEL-31) and three experimental cell lines (TD 1.4, TD 7.2 and TD 8) derived from UVB-induced melanocytic nevi in *Monodelphis domestica* were grown in vitro to assess the cytostatic IC-50 values for toremifene. The metastatic melanoma cell line, SK-MEL-31, was obtained from the American Type Culture Collection (Rockville, MD). Two additional human cell lines were derived from portions of surgically-excised large diameter, superficial spreading melanomas. TD 1.4 was developed from a benign melanoma, whereas TD 7.2 and TD 8 were derived from melanocytic hyperplasias. IC-50 values were determined from semi-log plots of percent cell survival vs. concentration of toremifene citrate.

Results

The mean plasma and tissue concentrations of toremifene in 6 animals following topical administration of 0.5 and 1 mg/day for 5 days are given in Table 6. Toremifene concentration in skin was more than 500-fold as compared to other tissues.

The 50 % growth inhibitory concentrations (IC-50) of the human and experimental cell lines for toremifene is shown in Table 7. Growth inhibitory effect of toremifene was very similar in all six cell lines of melanocyte origin. The IC-50s had a range of 5.8 - 9.6 μM .

Discussion

In the experiment we demonstrated that toremifene has a clear cytostatic effect on human and experimental melanomatous cell lines in vitro. Although a cytostatic effect was observed in all cell lines, the concentrations needed to produce this effect were relatively high. However, topical administration of toremifene produces skin concentrations that are far beyond these in vitro concentrations, suggesting that a clear cytostatic effect could be obtained on cutaneous melanoma in vivo.

Table 1. Toremifene concentrations following 5 days of IP vs. topical treatment with toremifene

<u>Tissue</u>	<u>IP</u>	<u>Topical</u>	<u>Topical/IP</u>
Tumor ($\mu\text{g/g}$)	7.08 (3.55 - 11.86)	1087.34 (23.47 - 1924.77)	153.58
Serum ($\mu\text{g/ml}$)	4.37 (0.1 - 12.79)	1.00 (0.46 - 1.84)	0.23
Brain ($\mu\text{g/g}$)	1.85 (1.17 - 2.20)	1.45 (1.29 - 1.61)	0.78
Uterus ($\mu\text{g/g}$)	29.97 (26.47 - 35.90)	2.94 (2.33 - 3.53)	0.10
Liver ($\mu\text{g/g}$)	14.25 (11.2 - 18.60)	4.21 (3.46 - 5.62)	0.30

Table 2. N-demethyltoremifene concentrations following IP vs. topical treatment

<u>Tissue</u>	<u>IP</u>	<u>Topical</u>	<u>Topical/IP</u>
Tumor (µg/g)	1.27 (0.88 - 1.74)	8.43 (1.15 - 13.86)	6.64
Serum (µg/ml)	0.18 (0.10 - 0.30)	0.08 (0.06 - 0.09)	0.44
Brain (µg/g)	0.49 (0.26 - 0.73)	0.29 (0.0 - 0.49)	0.59
Uterus (µg/g)	1.18 (1.02 - 1.51)	0.56 (0.38 - 0.76)	0.47
Liver (µg/g)	0.94 (0.92 - 0.98)	0.92 (0.80 - 1.10)	0.98

Table 3. Trans 4-hydroxytoremifene concentrations following IP vs. topical treatment

<u>Tissue</u>	<u>IP</u>	<u>Topical</u>	<u>Topical/IP</u>
Tumor (µg/g)	0.88 (0.64 - 1.06)	2.33 (0.82 - 3.26)	2.65
Serum (µg/ml)	0.16 (0.12 - 0.20)	0.10 (0.04 - 0.17)	0.63
Brain (µg/g)	0.35 (0.22 - 0.43)	0.35 (0.31 - 0.40)	1.00
Uterus (µg/g)	0.83 (0.46 - 1.05)	0.70 (0.50 - 0.80)	0.84
Liver (µg/g)	0.60 (0.56 - 0.66)	0.98 (0.51 - 1.43)	1.63

Table 4. Comparison of cellular concentrations of toremifene following in vitro exposure, intraperitoneal injection and topical administration

<u>Sample</u>	<u>Route of Administration</u>	<u>Toremifene Conc.</u>
In Vitro (Cell pellets)	Direct Application	0.149 µg/mg
In Vivo (Tumor)	Intraperitoneal Injection	0.007 µg/mg
In Vivo (Tumor)	Topical Administration	1.087 µg/mg

Concentrations are average of three determinations.

Table 5. Toremifene concentrations following a single dose IP vs. topical treatment toremifene (500 µg) in DMSO or methylcellulose

<u>Tissue</u>	<u>IP</u>	<u>DMSO</u>	<u>MC</u>	<u>DMSO/IP</u>	<u>MC/IP</u>
Tumor (µg/g)	2.57 (1.64-4.46)	4.65 (3.41-6.96)	1.80 (0.95-3.10)	1.81	0.70
Serum (µg/ml)	0.09 (0.04-0.14)	0.03 (0.004-0.04)	0.02 (0.00-0.04)	0.33	0.22
Uterus (µg/g)	23.60 (13.58-40.17)	0.92 (0.66-1.35)	1.10 (0.64-1.92)	0.04	0.05

Table 6. The mean concentration of toremifene in plasma (nmol/ml) and various tissues (nmol/g) following topical toremifene administration of 0.5 and 1 mg/day for 5 days in 6 male *Monodelphi domestica*.

	0.5 mg/day	1 mg/day
Plasma	0	0
Skin	1296.40 \pm 1003.93	1237.35 \pm 768.90
Liver	1.07 \pm 0.69	3.60 \pm 2.23
Testicles	1.52 \pm 2.13	0.52 \pm 0.05
Brain	0.82 \pm 0.99	0.82 \pm 0.62
Eyes	0	0.17 \pm 0.05
Heart	0	0.21 \pm 0.16

Table 7. IC-50 values of the human and experimental melanomatous cell lines for toremifene

	Cell line	IC-50 (μ M)
Human	TD 36	5.8
	TD 30 A	7.7
	SD-MEL-31	8.1
Experimental	TD 8	7.7
	TD 1.4	9.3
	TD 7.2	9.6

CLAIMS

1. A topical preparation comprising as active ingredient toremifene or one of its metabolites N-demethyltoremifene (4-chloro-1,2-diphenyl-[4-[2-(N-methylamino)ethoxy]phenyl]-1-butene) or 4-hydroxytoremifene (4-chloro-1-(4-hydroxyphenyl)-2-phenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene) or a pharmaceutically acceptable non-toxic salt thereof, together with one or more pharmaceutically acceptable excipients.
2. A preparation according to claim 1 which is in the form of an ointment, emulsion, lotion, solution, gel or cream.
3. A preparation according to claim 1 where the preparation is a transdermal delivery patch system.
4. A preparation according to claim 2 or 3 where the active ingredient is in the form of a complex of cyclodextrin or a cyclodextrin derivative.
5. A preparation according to any one of claims 1 to 4 where the active ingredient is toremifene or a pharmaceutically acceptable salt thereof.
6. A topical preparation according to any one of claims 1 to 5 for use in the treatment of breast cancer.
7. A topical preparation according to any one of claims 1 to 5 for use in the adjuvant therapy of breast cancer.
8. A topical preparation according to any one of claims 1 to 5 for use in the reversal of multidrug resistance of cancer cells to cytotoxic drugs.
9. A topical preparation according to any one of claims 1 to 5 or 8 for use in the treatment of melanoma, lymphoma, Kaposi's sarcoma or fungoides mycosis.

10. A method of treatment of breast cancer comprising administering topically to a subject in need of such treatment an effective amount of a topical preparation comprising as active ingredient toremifene or one of its metabolites N-demethyl-toremifene (4-chloro-1,2-diphenyl-[4-[2-(N-methylamino)ethoxy]-phenyl]-1-butene) or 4-hydroxytoremifene (4-chloro-1-(4-hydroxyphenyl)-2-phenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]-phenyl]-1-butene) or a pharmaceutically acceptable non-toxic salt thereof, together with one or more pharmaceutically acceptable excipients
11. A method for reversing the multidrug resistance of cancer cells to a cytotoxic drug comprising administering topically a multidrug resistance reversal effective amount of toremifene or one of its metabolites N-demethyltoremifene (4-chloro-1,2-diphenyl-[4-[2-(N-methylamino)ethoxy]-phenyl]-1-butene) or 4-hydroxytoremifene (4-chloro-1-(4-hydroxyphenyl)-2-phenyl-1-[4-[2-(N,N-dimethylamino)-ethoxy]phenyl]-1-butene) or a pharmaceutically acceptable non-toxic salt thereof, together with one or more pharmaceutically acceptable excipients, to a subject in need of such treatment.
12. A method of treatment of melanoma, lymphoma, Kaposi's sarcoma or fungoides mycosis comprising administering topically to a subject in need of such treatment an effective amount of a topical preparation comprising as active ingredient toremifene or one of its metabolites N-demethyltoremifene (4-chloro-1,2-diphenyl-[4-[2-(N-methylamino)ethoxy]-phenyl]-1-butene) or 4-hydroxytoremifene (4-chloro-1-(4-hydroxyphenyl)-2-phenyl-1-[4-[2-(N,N-dimethyl-amino)ethoxy]phenyl]-1-butene) or a pharmaceutically acceptable non-toxic salt thereof, together with one or more pharmaceutically acceptable excipients.




FIG. 1




FIG. 2




FIG. 3a




FIG. 3b

INTERNATIONAL SEARCH REPORT

PCT/FI 93/00119

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 A61K31/135; A61K9/70; A61K47/48		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	A61K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	US,A,4 990 538 (A.L.HARRIS) 5 February 1991 see claims 1-2 see column 2, line 28 - line 36 see column 3, line 1 - line 2	1-12
A	EP,A,0 095 875 (FARMOS GROUP) 7 December 1983 see claims 1,18-19 see page 4, line 31 - line 33 see page 25, line 22 - line 27 see page 26, line 1 - line 9	1-12
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
09 JUNE 1993		23. 06. 93
International Searching Authority		Signature of Authorized Officer
EUROPEAN PATENT OFFICE		SCARPONI U.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 93/00119

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
REMARK: Although claims are directed to a method of treatment of the human body by therapy (rule 39.1(4)PCT) the search has been carried out and based upon the alleged effects of the composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☒ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.